But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
